455,605 Shares in Tango Therapeutics, Inc. $TNGX Acquired by Boone Capital Management LLC

Boone Capital Management LLC bought a new stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 455,605 shares of the company’s stock, valued at approximately $14,242,000. Tango Therapeutics accounts for about 3.3% of Boone Capital Management LLC’s portfolio, making the stock its 13th biggest holding.

Several other hedge funds have also recently added to or reduced their stakes in the business. Invesco Ltd. boosted its position in Tango Therapeutics by 138.8% during the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock worth $97,000 after acquiring an additional 40,983 shares during the period. AQR Capital Management LLC acquired a new position in shares of Tango Therapeutics during the first quarter valued at $195,000. Dynamic Technology Lab Private Ltd raised its stake in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after purchasing an additional 15,037 shares in the last quarter. Woodline Partners LP raised its stake in shares of Tango Therapeutics by 28.3% during the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock valued at $693,000 after purchasing an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Tango Therapeutics by 270.6% in the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after purchasing an additional 257,668 shares during the period. Institutional investors own 78.99% of the company’s stock.

Insider Buying and Selling at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the transaction, the insider owned 115,743 shares in the company, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.50% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on TNGX. Mizuho increased their target price on shares of Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Leerink Partners boosted their price target on shares of Tango Therapeutics from $55.00 to $69.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Wolfe Research set a $35.00 price target on shares of Tango Therapeutics and gave the stock an “outperform” rating in a research report on Monday, June 8th. Weiss Ratings raised shares of Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, HC Wainwright increased their price objective on shares of Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Tango Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $43.46.

Tango Therapeutics Stock Performance

NASDAQ TNGX opened at $25.47 on Thursday. Tango Therapeutics, Inc. has a 1 year low of $6.25 and a 1 year high of $34.39. The business’s fifty day moving average is $27.90 and its two-hundred day moving average is $23.04. The stock has a market capitalization of $4.29 billion, a P/E ratio of -29.96 and a beta of 1.16.

Tango Therapeutics (NASDAQ:TNGX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.05). On average, research analysts forecast that Tango Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.